香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團已取得中國國家藥品監督管理局有關鹽酸普羅帕酮注射液（20ml∶70mg）的藥品生產註 冊批件，屬於化學藥品第3類，視同通過一致性評價，是國內企業第三家獲批。 鹽酸普羅帕酮注射液主要用於需治療的室上性心動過速，如房室交界性心動過速，WPW 綜合 症合併室上性心動過速或陣發性心房顫動，及需治療或致命的室性心動過速。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二六年一月三十日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 ...

石四药集团(02005)发布公告，集团已取得中国国家药品监督管理局有关新增2ml规格的复合磷酸氢钾注 射液的药品生产注册批件，属于化学药品第3类，视同通过一致性评价。复合磷酸氢钾注射液是复方制 剂，主要当口服或肠内营养无法进行、不足或有禁忌时，用于纠正成人和儿童患者的低磷血症及用于成 人和儿童患者的肠外营养。 ...

智通财经APP讯，石四药集团(02005)发布公告，集团已取得中国国家药品监督管理局有关新增2ml规格 的复合磷酸氢钾注射液的药品生产注册批件，属于化学药品第3类，视同通过一致性评价。复合磷酸氢 钾注射液是复方制剂，主要当口服或肠内营养无法进行、不足或有禁忌时，用于纠正成人和儿童患者的 低磷血症及用于成人和儿童患者的肠外营养。 ...

格隆汇1月26日丨石四药集团(02005.HK)公告，集团已取得中国国家药品监督管理局有关新增2ml规格的 复合磷酸氢钾注射液的药品生产注册批件，属于化学药品第3类，视同通过一致性评价。 复合磷酸氢钾注射液是复方制剂，主要当口服或肠内营养无法进行、不足或有禁忌时，用于纠正成人和 儿童患者的低磷血症及用于成人和儿童患者的肠外营养。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 - 1 - 石四藥集團有限公司(「本公司」，連同其附屬公司，「本集團」)董事局(「董事局」)欣然公告， 本集團已取得中國國家藥品監督管理局有關新增2ml 規格的複合磷酸氫鉀注射液的藥品生產註 冊批件，屬於化學藥品第3類，視同通過一致性評價。 複合磷酸氫鉀注射液是複方製劑，主要當口服或腸內營養無法進行、不足或有禁忌時，用於糾 正成人和兒童患者的低磷血症及用於成人和兒童患者的腸外營養。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二六年一月二十六日 自願公告 產品開發的最新進展 ...

Core Insights - The article highlights the net inflow and outflow of funds in the Hong Kong stock market, with Xiaomi Group, Tencent Holdings, and China Construction Bank leading in net inflows, while the Yingfu Fund, Hang Seng China Enterprises, and Southern Hang Seng Technology experienced the highest net outflows [1] Group 1: Net Inflows - Xiaomi Group-W (01810) recorded a net inflow of 1.07 billion, representing a 16.36% increase in its closing price [2] - Tencent Holdings (00700) saw a net inflow of 863 million, with a 7.49% increase in its closing price [2] - China Construction Bank (00939) had a net inflow of 699 million, with a significant 41.06% increase in its closing price [2] Group 2: Net Outflows - Yingfu Fund (02800) experienced the largest net outflow of 6.289 billion, reflecting a -31.44% change in its closing price [2] - Hang Seng China Enterprises (02828) had a net outflow of 2.880 billion, with a -17.89% change in its closing price [2] - Southern Hang Seng Technology (03033) faced a net outflow of 1.289 billion, showing a -11.37% change in its closing price [2] Group 3: Net Inflow Ratios - 361 Degrees (01361) led with a net inflow ratio of 74.40%, with a net inflow of 8.9117 million [3] - BRILLIANCE CHI (01114) followed with a net inflow ratio of 64.04%, amounting to a net inflow of 36.4910 million [3] - Qin Port Co. (03369) had a net inflow ratio of 61.05%, with a net inflow of 846,600 [3] Group 4: Net Outflow Ratios - Wisdom Hong Kong 100 (02825) had a net outflow ratio of -100.00%, with a net outflow of -18,200 [3] - Stone Pharmaceutical Group (02005) recorded a net outflow ratio of -68.86%, with a net outflow of -14.1501 million [3] - Dexion Shipping (02510) experienced a net outflow ratio of -53.53%, with a net outflow of -10.0204 million [3]

智通财经APP获悉，石四药集团(02005)、方正控股(00418)、天福(06868)、永升服务(01995)、VITASOY INT'L(00345)、天润云(02167)、绿城服务(02869)、亲亲食品(01583)、信利国际(00732)、天安卓健 (00383)、舜宇光学科技(02382)、吉利汽车(00175)、同方友友(01868)、心玮医疗-B(06609)、捷利交易宝 (08017)、威高股份(01066)、津上机床中国(01651)、碧桂园服务(06098)、宝胜国际(03813)、腾讯控股 (00700)、易点云(02416)、天伦燃气(01600)、名创优品(09896)、枫叶教育(01317)、小米集团- W(01810)、美丽田园医疗健康(02373)、绿茶集团(06831)、HYPEBEAST(00150)、美亨实业(01897)、多 点数智(02586)、巨子生物(02367)、思派健康(00314)、九毛九(09922)、KEEP(03650)、手回集团 (02621)、连连数字(02598)、汇通达网络(09878)、迈富时(02556)、叮当健康(09886)、家乡互动 ...

Summary of Key Points Core Viewpoint - The latest shareholder equity disclosures for several companies, including Zhongjia Guoxin, Boan Biotech, Fudan Zhangjiang, and others, were made on January 12, 2026, indicating significant changes in shareholdings among various institutional investors [1]. Group 1: Zhongjia Guoxin (00899) - Jiang Xiaojun increased holdings from 5.60 million shares to 16.80 million shares, representing a holding percentage of 3.77% [2] - Li Jiayi raised holdings from 23.39 million shares to 70.18 million shares, with a holding percentage of 15.76% [2] - Lin Bilin increased holdings from 0.10 million shares to 31.30 million shares, now holding 7.03% [2] - FULL TENDA DEVELOPMENT increased holdings from 23.88 million shares to 71.65 million shares, holding 16.09% [2] - GREEN DEER HOLDINGS LIMITED increased holdings from 0.10 million shares to 31.30 million shares, now holding 7.03% [2] - Yao Jigen increased holdings from 24.96 million shares to 74.88 million shares, with a holding percentage of 16.82% [2] Group 2: Boan Biotech (06955) - Yantai Green Leaf Pharmaceutical Holdings reduced holdings from 361 million shares to 311 million shares, now holding 49.90% [2] - Luye Geneora Holding Limited acquired 50 million shares, holding 8.03% [2] - AsiaPharm Investments reduced holdings from 361 million shares to 311 million shares, now holding 49.90% [2] - Shandong Green Leaf Pharmaceutical reduced holdings from 361 million shares to 311 million shares, now holding 49.90% [2] - Luye Pharma Hong Kong Limited reduced holdings from 361 million shares to 311 million shares, now holding 49.90% [2] Group 3: Other Companies - Fudan Zhangjiang (01349): Yang Zongmeng reduced holdings from 59.33 million shares to 55.79 million shares, now holding 7.85% [2] - Prosperity Industrial Trust (00778): ESR Asset Management increased holdings from 76.05 million shares to 80.57 million shares, now holding 3.92% [2] - Shishi Pharmaceutical Group (02005): Qu Jiguang maintained holdings at 1.233 billion shares, holding 41.79% [2] - Zheli Holdings (02209): Lei Baicheng slightly reduced holdings from 31.31 million shares to 31.05 million shares, now holding 7.43% [2]

智通财经APP讯，石四药集团(02005)发布公告，于2026年1月9日，该公司斥资138.87万港元回购45.6万 股。 ...

石四药集团(02005)发布公告，于2026年1月9日，该公司斥资138.87万港元回购45.6万股。 ...